Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865696 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions
A Phase 1 study, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00865696 is a Phase 1 study that has completed, run by Actavis. The registered enrollment target is 32 participants.
The verdict
NCT00865696, a Phase 1 study, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the relative bioavailability of 15 mg Mirtazapine Tablets by Purepac Pharmaceutical Co with that of 15 mg REMERON® Tablets by Organon Inc. following a single oral dose (1 x 15 mg) in healthy adult volunteers under fasting conditions.
Interventions
- DRUG Mirtazapine 15 mg tablets, single dose
- DRUG REMERON® 15 mg tablets, single dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2001-09 |
| Est. Completion | 2001-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865696
The ClinicalTrials.gov registry entry for NCT00865696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirtazapine 15 mg tablets, single dose is the first listed.
NCT00865696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00865696 about?
NCT00865696 is a clinical study titled "A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions". The purpose of this study is to compare the relative bioavailability of 15 mg Mirtazapine Tablets by Purepac Pharmaceutical Co with that of 15 mg REMERON® Tablets by Organon Inc. following a single oral dose (1 x 15 mg) in healthy adult volunteers under fasting conditions.
What is the current status of trial NCT00865696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2001-09. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00865696?
The interventions under investigation include: Mirtazapine 15 mg tablets, single dose (DRUG), REMERON® 15 mg tablets, single dose (DRUG).
Who is sponsoring clinical trial NCT00865696?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.